These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24767679)

  • 1. A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1.
    Akdeli N; Riemann K; Westphal J; Hess J; Siffert W; Bachmann HS
    Mol Cancer; 2014 Apr; 13():87. PubMed ID: 24767679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
    Liu J; Lu KH; Liu ZL; Sun M; De W; Wang ZX
    BMC Cancer; 2012 Nov; 12():519. PubMed ID: 23151088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of PLK1 through competition between hnRNPK, miR-149-3p and miR-193b-5p.
    Shin CH; Lee H; Kim HR; Choi KH; Joung JG; Kim HH
    Cell Death Differ; 2017 Nov; 24(11):1861-1871. PubMed ID: 28708135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region.
    Zhang J; Wang S; Kern S; Cui X; Danner RL
    J Biol Chem; 2007 Jan; 282(2):1003-9. PubMed ID: 17121839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
    Ito T; Sato F; Kan T; Cheng Y; David S; Agarwal R; Paun BC; Jin Z; Olaru AV; Hamilton JP; Selaru FM; Yang J; Matsumura N; Shimizu K; Abraham JM; Shimada Y; Mori Y; Meltzer SJ
    Int J Cancer; 2011 Nov; 129(9):2134-46. PubMed ID: 21170987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
    Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
    FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like kinase 1 inhibits the activity of positive transcription elongation factor of RNA Pol II b (P-TEFb).
    Jiang L; Huang Y; Deng M; Liu T; Lai W; Ye X
    PLoS One; 2013; 8(8):e72289. PubMed ID: 23977272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinome inhibition reveals a role for polo-like kinase 1 in targeting post-transcriptional control in cancer.
    Al-Qahtani QH; Moghrabi WN; Al-Yahya S; Al-Haj L; Al-Saif M; Mahmoud L; Al-Mohanna F; Al-Souhibani N; Alaiya A; Hitti E; Khabar KSA
    Mol Oncol; 2021 Aug; 15(8):2120-2139. PubMed ID: 33411958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
    Park JE; Kim TS; Kim BY; Lee KS
    Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53-dependent repression of polo-like kinase-1 (PLK1).
    McKenzie L; King S; Marcar L; Nicol S; Dias SS; Schumm K; Robertson P; Bourdon JC; Perkins N; Fuller-Pace F; Meek DW
    Cell Cycle; 2010 Oct; 9(20):4200-12. PubMed ID: 20962589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-296-5p suppresses papillary thyroid carcinoma cell growth via targeting PLK1.
    Zhou SL; Tang QL; Zhou SX; Ren RZ
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2084-2091. PubMed ID: 30915753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
    Cheng MW; Wang BC; Weng ZQ; Zhu XW
    Acta Histochem; 2012 Sep; 114(5):503-9. PubMed ID: 22000864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of the catalytic domain of human polo-like kinase 1.
    Kothe M; Kohls D; Low S; Coli R; Cheng AC; Jacques SL; Johnson TL; Lewis C; Loh C; Nonomiya J; Sheils AL; Verdries KA; Wynn TA; Kuhn C; Ding YH
    Biochemistry; 2007 May; 46(20):5960-71. PubMed ID: 17461553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.
    Murugan RN; Park JE; Kim EH; Shin SY; Cheong C; Lee KS; Bang JK
    Mol Cells; 2011 Sep; 32(3):209-20. PubMed ID: 21809214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
    Sero V; Tavanti E; Vella S; Hattinger CM; Fanelli M; Michelacci F; Versteeg R; Valsasina B; Gudeman B; Picci P; Serra M
    Invest New Drugs; 2014 Dec; 32(6):1167-80. PubMed ID: 25193492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
    Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
    PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
    [TBL] [Abstract][Full Text] [Related]  

  • 19.  p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
    Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
    Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation.
    Lasek AL; McPherson BM; Trueman NG; Burkard ME
    PLoS One; 2016; 11(2):e0150225. PubMed ID: 26919439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.